Clinical Trial Update: 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab [NA]

View source ↗

Summary

The clinical trial evaluating 64CuATSM and hypoxia in stage IV non-small cell lung cancer using carboplatin, paclitaxel, and bevacizumab has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Carcinoma, Non-Small-Cell Lung | NA | Status: WITHDRAWN